Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignacio Aliagas

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Journal of Medicinal Chemistry|April 5, 2017
Sustainable Practices in Medicinal Chemistry Part 2: Green by DesignIgnacio Aliagas, Raphaëlle Berger, Kristin Goldberg, et al.
Journal of Computer-Aided Molecular Design|April 30, 2015
An integrated suite of modeling tools that empower scientists in structure- and property-based drug designJianwen A Feng, Ignacio Aliagas, Philippe Bergeron, et al.
Bioorganic & Medicinal Chemistry Letters|June 28, 2016
Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitorsWendy Lee, James J Crawford, Ignacio Aliagas, et al.
ACS Medicinal Chemistry Letters|June 24, 2015
Leveraging the Pre-DFG Residue Thr-406 To Obtain High Kinase Selectivity in an Aminopyrazole-Type PAK1 Inhibitor SeriesJoachim Rudolph, Ignacio Aliagas, James J Crawford, et al.
Journal of Medicinal Chemistry|June 2, 2015
Structure-Guided Design of Group I Selective p21-Activated Kinase InhibitorsJames J Crawford, Wendy Lee, Ignacio Aliagas, et al.
Journal of Medicinal Chemistry|May 1, 2009
A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora BIgnacio Aliagas-Martin, Dan Burdick, Laura Corson, et al.
Nature|February 5, 2010
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthGeorgia Hatzivassiliou, Kyung Song, Ivana Yen, et al.
ACS Medicinal Chemistry Letters|December 30, 2015
Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar MoietyChudi O Ndubaku, James J Crawford, Joy Drobnick, et al.
Journal of Medicinal Chemistry|February 17, 2012
Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic propertiesSimon Mathieu, Stefan N Gradl, Li Ren, et al.
Journal of Medicinal Chemistry|May 12, 2016
Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic WindowJoachim Rudolph, Lesley J Murray, Chudi O Ndubaku, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Medicinal Chemistry|April 5, 2017
Sustainable Practices in Medicinal Chemistry Part 2: Green by DesignIgnacio Aliagas, Raphaëlle Berger, Kristin Goldberg, et al.
Journal of Computer-Aided Molecular Design|April 30, 2015
An integrated suite of modeling tools that empower scientists in structure- and property-based drug designJianwen A Feng, Ignacio Aliagas, Philippe Bergeron, et al.
Bioorganic & Medicinal Chemistry Letters|June 28, 2016
Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitorsWendy Lee, James J Crawford, Ignacio Aliagas, et al.
ACS Medicinal Chemistry Letters|June 24, 2015
Leveraging the Pre-DFG Residue Thr-406 To Obtain High Kinase Selectivity in an Aminopyrazole-Type PAK1 Inhibitor SeriesJoachim Rudolph, Ignacio Aliagas, James J Crawford, et al.
Journal of Medicinal Chemistry|June 2, 2015
Structure-Guided Design of Group I Selective p21-Activated Kinase InhibitorsJames J Crawford, Wendy Lee, Ignacio Aliagas, et al.
Journal of Medicinal Chemistry|May 1, 2009
A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora BIgnacio Aliagas-Martin, Dan Burdick, Laura Corson, et al.
Nature|February 5, 2010
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthGeorgia Hatzivassiliou, Kyung Song, Ivana Yen, et al.
ACS Medicinal Chemistry Letters|December 30, 2015
Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar MoietyChudi O Ndubaku, James J Crawford, Joy Drobnick, et al.
Journal of Medicinal Chemistry|February 17, 2012
Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic propertiesSimon Mathieu, Stefan N Gradl, Li Ren, et al.
Journal of Medicinal Chemistry|May 12, 2016
Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic WindowJoachim Rudolph, Lesley J Murray, Chudi O Ndubaku, et al.
Pageof 3